Isolation and partial characterization of cyclic lipopeptide antibiotics produced by Paenibacillus ehimensis B7

BMC Microbiology

Mingxu Song¹  Linfei Shou²  Yu Hu¹  Zhaohui Huang¹ 

[1] Clinical laboratory, the Fourth People’s Hospital of Wuxi, 200 Huihe Road, Wuxi, 214062, China;Institute for the Control of Agro-chemicals of Zhejiang Province, 29 East Fengqi Road, Hangzhou, 310020, China

关键词: Drug-resistant bacteria;    Lipopeptide antibiotics;    Paenibacillus ehimensis;   

Others  :  1143867
DOI  :  10.1186/1471-2180-13-87

 received in 2012-10-09, accepted in 2013-04-11,  发布年份 2013

【 摘 要 】

Background

The prevalence of drug-resistant bacteria has encouraged the search for novel antimicrobial compounds. Food-associated microorganisms, as a source of new antibiotics, have recently received considerable attention. The objective of this study was to find novel antimicrobial agents produced by food microorganisms.

Results

A bacterial strain B7, which has potent antimicrobial activity, was isolated from a sample of dairy waste. This strain was identified as Paenibacillus ehimensis based on the 16S rRNA gene sequence analysis, physiological and biochemical characterization. Two active compounds (PE1 and PE2) were obtained from P. ehimensis B7. Mass spectrometry (MS) analysis showed that the molecular masses of PE1 and PE2 were 1,114 and 1,100 Da, respectively. The tandem MS and amino acid analysis indicated that PE1 and PE2 were analogs of polypeptin, and PE2 was characterized as a new member of this family. Both compounds were active against all tested bacterial pathogens, including methicillin resistant Staphylococcus aureus, Escherichia coli, and pan-drug resistant Pseudomonas aeruginosa clinical isolate. Time-kill assays demonstrated that at 4 × MIC (minimum inhibitory concentration), PE1 and PE2 rapidly reduced the number of viable cells by at least 3-orders of magnitude, indicating that they were bactericidal antibiotics.

Conclusions

In the present work, two cationic lipopeptide antibiotics (PE1 and PE2) were isolated from P. ehimensis B7 and characterized. These two peptides showed broad antimicrobial activity against all tested human pathogens and are worthy of further study.

【 授权许可】

   
2013 Huang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Arias CA, Murray BE: Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. New Engl J Med 2009, 360(5):439-443.
• [2]Fischbach MA, Walsh CT: Antibiotics for emerging pathogens. Science 2009, 325(5944):1089-1093.
• [3]Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, Cardo DM: Estimating health care-associated infections and deaths in US hospitals, 2002. Public Health Rep 2007, 122(2):160.
• [4]Benquan W, Yingchun T, Kouxing Z, Tiantuo Z, Jiaxing Z, Shuqing T: Staphylococcus heterogeneously resistant to vancomycin in China and antimicrobial activities of imipenem and vancomycin in combination against It. J Clin Microbiol 2002, 40(3):1109-1112.
• [5]Zhang R, Eggleston K, Rotimi V, Zeckhauser RJ: Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Global Health 2006, 2(6):1-14.
• [6]Peleg AY, Hooper DC: Hospital-acquired infections due to gram-negative bacteria. New Engl J Med 2010, 362(19):1804-1813.
• [7]Pagès JM, James CE, Winterhalter M: The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 2008, 6(12):893-903.
• [8]Velkov T, Thompson PE, Nation RL, Li J: Structure-Activity Relationships of Polymyxin Antibiotics. J Med Chem 2010, 53(5):1898.
• [9]Vaara M, Siikanen O, Apajalahti J, Fox J, Frimodt-Møller N, He H, Poudyal A, Li J, Nation RL, Vaara T: A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob Agents Chemother 2010, 54(8):3341-3346.
• [10]Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL: Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2006, 6(1):29-40.
• [11]He Z, Kisla D, Zhang L, Yuan C, Green-Church KB, Yousef AE: Isolation and identification of a Paenibacillus polymyxa strain that coproduces a novel lantibiotic and polymyxin. Appl Environ Microbiol 2007, 73(1):168-178.
• [12]Guo Y, Huang E, Yuan C, Zhang L, Yousef AE: Isolation of a Paenibacillus sp. Strain and Structural Elucidation of Its Broad-Spectrum Lipopeptide Antibiotic. Appl Environ Microbiol 2012, 78(9):3156-3165.
• [13]Delves-Broughton J: Nisin and its application as a food preservative. Int J Dairy Technol 2007, 43(3):73-76.
• [14]Wu XC, Qian CD, Fang HH, Wen YP, Zhou JY, Zhan ZJ, Ding R, Li O, Gao H: Paenimacrolidin, a novel macrolide antibiotic from Paenibacillus sp. F6-B70 active against methicillin-resistant Staphylococcus aureus. Microb Biotechnol 2011, 4(4):491-502.
• [15]Wu XC, Shen XB, Ding R, Qian CD, Fang HH, Li O: Isolation and partial characterization of antibiotics produced by Paenibacillus elgii B69. FEMS Microbiol Lett 2011, 310(1):32-38.
• [16]Weisburg WG, Barns SM, Pelletier DA, Lane DJ: 16S ribosomal DNA amplification for phylogenetic study. J Bacteriol 1991, 173(2):697-703.
• [17]Tamura K, Dudley J, Nei M, Kumar S: MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24(8):1596-1599.
• [18]Sopirala MM, Mangino JE, Gebreyes WA, Biller B, Bannerman T, Balada-Llasat JM, Pancholi P: Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010, 54(11):4678-4683.
• [19]Fujii K, Ikai Y, Oka H, Suzuki M, Harada K: A nonempirical method using LC/MS for determination of the absolute configuration of constituent amino acids in a peptide: combination of Marfey's method with mass spectrometry and its practical application. Anal Chem 1997, 69(24):5146-5151.
• [20]Lee JS, Pyun YR, Bae KS: Transfer of Bacillus ehimensis and Bacillus chitinolyticus to the genus Paenibacillus with emended descriptions of Paenibacillus ehimensis comb. nov. and Paenibacillus chitinolyticus comb. nov. Int J Syst Evol Microbiol 2004, 54(3):929-933.
• [21]Li J, Turnidge J, Milne R, Nation RL, Coulthard K: In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosaIsolates from Patients with Cystic Fibrosis. Antimicrob Agents Chemother 2001, 45(3):781-785.
• [22]Qian CD, Wu XC, Teng Y, Zhao WP, Li O, Fang SG, Huang ZH, Gao HC: Battacin (Octapeptin B5), a New Cyclic Lipopeptide Antibiotic from Paenibacillus tianmuensis Active against Multidrug-Resistant Gram- Negative Bacteria. Antimicrob Agents Chemother 2012, 56(3):1458-1465.
• [23]Chung YR, Kim CH, Hwang I, Chun J: Paenibacillus koreensis sp. nov., a new species that produces an iturin-like antifungal compound. Int J Syst Evol Microbiol 2000, 50(4):1495-1500.
• [24]Teng Y, Zhao W, Qian C, Li O, Zhu L, Wu X: Gene cluster analysis for the biosynthesis of elgicins, novel lantibiotics produced by paenibacillus elgii B69. BMC Microbiol 2012, 12(1):45. BioMed Central Full Text
• [25]Sogn JA: Structure of the peptide antibiotic polypeptin. J Med Chem 1976, 19(10):1228-1231.
• [26]Takeuchi Y, Murai A, Takahara Y, Kainosho M: The structure of permetin A, a new polypeptin type antibiotic produced by Bacillus circulans. J Antibiot 1979, 32(2):121.
• [27]Sugawara K, Konishi M, Kawaguchi H: BMY-28160, a new peptide antibiotic. J Antibiot 1984, 37(10):1257-1259.
• [28]Ding R, Wu XC, Qian CD, Teng Y, Li O, Zhan ZJ, Zhao YH: Isolation and identification of lipopeptide antibiotics from Paenibacillus elgii B69 with inhibitory activity against methicillin-resistant Staphylococcus aureus. J Microbiol 2011, 49(6):942-949.
• [29]Falagas ME, Kasiakou SK, Saravolatz LD: Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005, 40(9):1333-1341.
• [30]Hancock REW: Peptide antibiotics. Lancet 1997, 349(9049):418-422.
• [31]Jenssen H, Hamill P, Hancock REW: Peptide antimicrobial agents. Clin Microbiol Rev 2006, 19(3):491-511.